Lyra Therapeutics, Inc.
Harlan Waksal
Lyra Therapeutics, Inc.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Harlan Waksal
Lyra Therapeutics, Inc. reported in an 8-K filed August 1, 2025 that Harlan Waksal resigned as Class II member of the Board of Directors, effective August 1, 2025. Lyra Therapeutics, Inc. reported in an 8-K filed August 1, 2025 that Harlan Waksal was terminated as Executive Chairman, effective August 1, 2025. The proxy statement of Lyra Therapeutics, Inc. reports total compensation of $5,027,375 for Harlan Waksal in fiscal 2022, including a base salary of $175,385.
“On the same date, Dr. Waksal resigned as a Class II member of the Board of Directors (the "Board").”
“On August 1, 2025, Lyra Therapeutics, Inc. (the "Company") and Harlan W. Waksal, M.D., the Company's Executive Chairman, agreed to terminate his employment effective immediately.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Lyra Therapeutics, Inc.
Proxy statement
CurrentStart not stated–present
-
Lyra Therapeutics, Inc.
Chairman
SEC 8-K
2022-02-16–2025-08-01
-
Lyra Therapeutics, Inc.
Board Member
Proxy statement
2022-01-01–2025-08-01
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Lyra Therapeutics, Inc. | Executive Chairman | $175,385 | $5,027,375 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.